Evidence map›Paper›PMID 36992901›Full record

ArticleDrug design, development and therapy2023

Synthesis and Biological Evaluation of Gentiopicroside Derivatives as Novel Cyclooxygenase-2 Inhibitors with Anti-Inflammatory Activity.

Guojin Ren, Qili Zhang, Pengfei Xia, Jie Wang, Pengxia Fang, Xiaojie Jin, Xuejing Peng, Yanli Xu, Jian Zhang, Lei Zhao

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Guojin Ren *Gansu University of Chinese Medicine, Lanzhou, 730000, People's Republic of China.ORCID 0000-0001-9111-6161
Qili Zhang *Gansu University of Chinese Medicine, Lanzhou, 730000, People's Republic of China.
Pengfei XiaGansu University of Chinese Medicine, Lanzhou, 730000, People's Republic of China.ORCID 0000-0002-3956-6509
Jie WangGansu University of Chinese Medicine, Lanzhou, 730000, People's Republic of China.ORCID 0000-0003-2494-2695
Pengxia FangGansu University of Chinese Medicine, Lanzhou, 730000, People's Republic of China.ORCID 0000-0002-5586-3140
Xiaojie JinGansu University of Chinese Medicine, Lanzhou, 730000, People's Republic of China.ORCID 0000-0002-1467-6269
Xuejing PengGansu University of Chinese Medicine, Lanzhou, 730000, People's Republic of China.
Yanli XuGansu University of Chinese Medicine, Lanzhou, 730000, People's Republic of China.ORCID 0000-0002-3957-1412
Jian ZhangGansu University of Chinese Medicine, Lanzhou, 730000, People's Republic of China.ORCID 0000-0001-8984-1516
Lei ZhaoGansu University of Chinese Medicine, Lanzhou, 730000, People's Republic of China.ORCID 0000-0003-2349-8780
Gansu University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Nonsteroidal anti-inflammatory drugs cause a series of adverse reactions. Thus, the search for new cyclooxygenase-2 selective inhibitors have become the main direction of research on anti-inflammatory drugs. Gentiopicroside is a novel selective inhibitor of cyclooxygenase-2 from Chinese herbal medicine. However, it is highly hydrophilic owing to the presence of the sugar fragment in its structure that reduces its oral bioavailability and limits efficacy. This study aimed to design and synthesize novel cyclooxygenase-2 inhibitors by modifying gentiopicroside structure and reducing its polarity. Materials and Methods: We introduced hydrophobic acyl chloride into the gentiopicroside structure to reduce its hydrophilicity and obtained some new derivatives. Their in vitro anti-inflammatory activities were evaluated against NO, TNF-α, PGE Results: A total of 21 novel derivatives were synthesized, and exhibit lower polarities than the gentiopicroside. Most compounds have good in vitro anti-inflammatory activity. The in vivo activity results demonstrated that 8 compounds were more active than gentiopicroside. The inhibition rate of some compounds was higher than celecoxib. Molecular docking predicted that 6 compounds could bind to cyclooxygenase-2 and had high docking scores in accordance with their potency of the anti-inflammatory activity. The confirmatory experiment proved that these 6 compounds had significant inhibitory effect against cyclooxygenase-2 enzyme. Structure-activity relationship analysis presumed that the para-substitution with the electron-withdrawing groups may benefit the anti-inflammatory activity. Conclusion: These gentiopicroside derivatives especially

Indexed as

Anti-Inflammatory AgentsCyclooxygenase 2 InhibitorsAnimalsAnti-Inflammatory Agents, Non-SteroidalCyclooxygenase 2EdemaIridoid GlucosidesMiceMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAnti-Inflammatory AgentsAnti-Inflammatory Agents, Non-SteroidalCyclooxygenase 2Cyclooxygenase 2 InhibitorsgentiopicrosideIridoid Glucosidesanti-inflammatorycyclooxygenase-2 inhibitorsgentiopicroside derivativesmolecular dockingstructural modification

Identifiers

PMID36992901
PMCPMC10042259
OpenAlexW4360616309

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.